The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2022 | How novel technologies and machine learning are impacting drug research in amyloidosis
Joost Schymkovitz
• 5 Sep 2022
Joost Schymkovitz, PhD, KU Leuven, Leuven, Belgium, briefly explains how novel technologies and machine learning are impacting drug research and allowing researchers to better understand the structure of amyloid proteins. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
